Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $168.33 million, up 24.2$0.36, compared to -$0.02 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of$148.8 million, representing a surprise of +13.12%. The company delivered an EPS surprise of -2.70%, with the consensus EPS estimate being $0.37. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...